Menu
ncarol.com
  • Home
  • Business
  • Real Estate
  • Health
  • Music
  • Services
  • Beauty
  • Finance
  • Financial
ncarol.com

Relecura Makes Patent Innovation Research Platform Free to Coronavirus Researchers in Wake of Pandemic
ncarol.com/10051865

Trending...
  • Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
  • A Well-Fed World, Youth Climate Save and PAN International Launch PHRESH: A Global Directory of Plant-Based Hunger Relief Organizations
  • Kaltra Launches Next-Gen MCHEdesign With Full Integration Into MCHEselect — Instant Simulation & Seamless Microchannel Coil Workflow
Relecura Inc
PLEASANTON, Calif. - ncarol.com -- Relecura Inc., a leading provider of AI-powered patent and scientific innovation research,  today announced that Coronavirus researchers across the globe who are working on discovering a solution to the crisis will have free access to its premium research platform until May 31, 2020. Using Relecura's premium research platform, researchers can find and build on existing IP and patent research that will aid them in finding solutions to the current COVID-19 world pandemic.

Interested researchers are invited to take advantage of this unique opportunity by emailing their name, title, work email and company name to researcher@relecura.com.

"The solution to the current crisis we're facing lies in the hands of researchers. Giving them access to the vast amount of existing technical knowledge that is available and the tools to process it to gain greater insight is our way of helping them help us," said George Koomullil, founder of Relecura Inc. "It's also a small way for us to demonstrate our thanks."

Relecura has published two research reports on Coronavirus to assist the research community. The first report, titled Coronavirus Patent Landscape, studies patents related to Coronavirus remedies and provides insights into patent data ranging from antigens and chemotherapeutics to gene therapy and supportive medication. On the other hand, Technical Exploration on Coronavirus explores topics related to Coronaviruses using the technical search engine Tech Explorer.

More on ncarol.com
  • eJoule Inc Participates in Silicon Dragon CES 2026
  • HBZBZL Unveils "Intelligent Ecosystem" Strategy: Integrating AI Analytics with Web3 Incubation
  • Kaltra Launches Next-Gen MCHEdesign With Full Integration Into MCHEselect — Instant Simulation & Seamless Microchannel Coil Workflow
  • A Well-Fed World, Youth Climate Save and PAN International Launch PHRESH: A Global Directory of Plant-Based Hunger Relief Organizations
  • Guests Can Save 25 Percent Off Last Minute Bookings at KeysCaribbean's Village at Hawks Cay Villas

About Relecura:

Relecura Inc is a software product company based in the San Francisco Bay Area. It's subsidiary, Relecura Technologies Pvt. Ltd., is in Bangalore. The company's full-stack cognitive cloud platform aids in managing strategic decisions by drawing powerful insights from patents and scientific literature using artificial intelligence, machine learning and natural language processing. Relecura's enterprise platform integrates the discovery and analysis of public documents with internal company documents, and thus builds a single knowledge base for organization-wide usage. Relecura has an API to help create custom tools for IP and business intelligence. For more details visit www.relecura.com.

Contact
George Koomullil
***@relecura.com


Source: Relecura Inc

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026
  • Elderhaus Receives 2025 Grant from The Endowment to Strengthen Services and Expand Community Impact
  • CredHub and Real Property Management Join Forces to Empower Franchise Owners with Rental Payment Credit Reporting Solutions
  • Leimert Park Announces Weeklong Kwanzaa Festival & Kwanzaa Parade Celebrating Black History, Culture, and Community
  • Renowned Alternative Medicine Specialist Dr. Sebi and His African Bio Mineral Balance Therapy Are the Focus of New Book
  • Psychiatric Drug Damage Ignored for Decades; CCHR Demands Federal Action
  • Why Millions Are Losing Sexual Sensation, And Why It's Not Age, Hormones, or Desire
  • Justin Jeansonne An Emerging Country Singer-Songwriter Music Fans Have Been Waiting For…a True Maverick
  • Russellville Huntington Learning Center Expands Access to Literacy Support; Approved Provider Under Arkansas Department of Education
  • UK Financial Ltd Launches U.S. Operations Following Delaware Approval
  • Pinealage: the app that turns strangers into meditation companions — in crowdfunding phase
  • "Micro-Studio": Why San Diegans are Swapping Crowded Gyms for Private, One-on-One Training at Sweat Society
  • Beycome Closes $2.5M Seed Round Led by InsurTech Fund
  • Tru by Hilton Columbia South Opens to Guests
  • Christy Sports donates $56K in new gear to SOS Outreach to help kids hit the slopes
  • "BigPirate" Sets Sail: A New Narrative-Driven Social Casino Adventure
  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026
  • Fayetteville Concrete Contractors Serves Cumberland County with Concrete Solutions
  • Women's Everyday Safety Is Changing - The Blue Luna Shows How
  • Microgaming Unveils Red Papaya: A New Studio Delivering Cutting-Edge, Feature-Rich Slots
_catLbl0 _catLbl1

Popular on ncarol.com

  • Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 1398
  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026 - 110
  • "Micro-Studio": Why San Diegans are Swapping Crowded Gyms for Private, One-on-One Training at Sweat Society
  • Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
  • A Well-Fed World, Youth Climate Save and PAN International Launch PHRESH: A Global Directory of Plant-Based Hunger Relief Organizations
  • Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
  • Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure
  • VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
  • Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform
  • LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio

Similar on ncarol.com

  • eJoule Inc Participates in Silicon Dragon CES 2026
  • Kaltra Launches Next-Gen MCHEdesign With Full Integration Into MCHEselect — Instant Simulation & Seamless Microchannel Coil Workflow
  • A Well-Fed World, Youth Climate Save and PAN International Launch PHRESH: A Global Directory of Plant-Based Hunger Relief Organizations
  • Trump's Executive Order Rescheduling Cannabis: Accelerating M&A in a Multibillion-Dollar Industry
  • Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
  • Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026
  • Elderhaus Receives 2025 Grant from The Endowment to Strengthen Services and Expand Community Impact
  • CredHub and Real Property Management Join Forces to Empower Franchise Owners with Rental Payment Credit Reporting Solutions
  • Renowned Alternative Medicine Specialist Dr. Sebi and His African Bio Mineral Balance Therapy Are the Focus of New Book
  • Psychiatric Drug Damage Ignored for Decades; CCHR Demands Federal Action
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute